193085-24-4

Usage

Uses

Used in Pharmaceutical Industry:
1-BOC-PIPERIDIN-4-YLIDENE-ACETIC ACID is used as a building block for the development of various pharmaceuticals. Its unique structure and the presence of the BOC protecting group allow for the creation of diverse drug candidates with potential therapeutic applications.
Used in Agrochemical Industry:
1-BOC-PIPERIDIN-4-YLIDENE-ACETIC ACID is utilized as a key intermediate in the synthesis of agrochemicals. Its ability to be modified into different derivatives makes it a valuable component in the development of new pesticides, herbicides, and other agricultural chemicals.
Used in Organic Synthesis:
1-BOC-PIPERIDIN-4-YLIDENE-ACETIC ACID is employed as a versatile intermediate in organic synthesis. Its reactivity and structural features enable the production of a wide range of organic compounds for various applications, including the synthesis of complex molecules and the development of new chemical processes.
Used in Drug Discovery and Development:
1-BOC-PIPERIDIN-4-YLIDENE-ACETIC ACID is used as a starting material in drug discovery and development. Its potential pharmacological properties and the ability to be modified into various derivatives make it a promising candidate for the creation of new drugs with improved efficacy and safety profiles.

InChI:InChI=1/C12H19NO4/c1-12(2,3)17-11(16)13-6-4-9(5-7-13)8-10(14)15/h8H,4-7H2,1-3H3,(H,14,15)

Upstream product

• 135716-08-4 tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate 
• 41979-39-9 4-piperidone hydrochloride 
• 169206-65-9 1-tert-butoxycarbonyl-4-[(methoxycarbonyl)methylene]piperidine 
• 84839-55-4 tert.butyl 1-tert.butyloxycarbonyl-Δ^4,α-piperidineacetate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 193085-25-5 4-[(methyl-{1-[methyl-(1-methylcarbamoyl-2-phenyl-ethyl)-carbamoyl]-2-naphthalen-2-yl-ethyl}-carbamoyl)-methylene]-piperidine-1-carboxylic acid tert-butyl ester 
• 1045708-80-2 4-[(3,4-difluoro-benzylcarbamoyl)-methylene]-piperidine-1-carboxylic acid tert-butyl ester 
• 1351940-60-7 tert-butyl 4-(2-(4-(3-chloro-4-(pyridin-2-yl-methoxy)phenylamino)-3-cyano-7-(tetrahydrofuran-3-yl-oxy)quinolin-6-yl-amino)-2-oxoethylidene)piperidine-1-carboxylate 
• 1426946-00-0 C₂₂H₃₀N₂O₆ 
• 1426946-06-6 C₂₁H₂₈N₄O₃S 
• 1426946-05-5 C₂₁H₂₇ClN₄O₃S 
• 1426946-02-2 C₂₃H₂₈N₄O₃ 
• 1381841-45-7 C₂₀H₂₀ClN₃ 
• 151238-69-6 C₂₀H₂₀FN₃ 
• 1005195-59-4 N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide trifluoroacetate 
• 1005195-58-3 N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide 
• 1005194-71-7 N-(4-(3-ethynylphenylamino)quinazolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide 
• 1005194-69-3 N-(4-(3-ethynylphenylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide 
• 1005195-57-2 tert-butyl 4-(2-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino) quinazolin-6-ylamino)-2-oxoethylidene) piperidine-1-carboxylate 

Relevant academic research and scientific papers

GLP-1R AGONISTS AND USES THEREOF

Provided herein are compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

Synthesis, biological evaluation and SAR studies of benzimidazole derivatives as H1-antihistamine agents

A series of benzimidazole derivatives have been designed, synthesized and evaluated for H1 antihistamine activity. Six compounds have showed potent antihistamine H1 activity. The primary SAR analysis indicated that benzyl or benzylidinyl substituted on the exo-nitrogen atom and C2 of the benzimidazole were significant. Further experiments indicated that compound 17d displayed excellent activity to reduce mast cell degranulation, moderate anti-PAF activity and decreased potency on hERG compared to astermizole. Hence compound 17d could serve as anti-allergic agent for further development.

INREVERSIBLE PROTEIN TYROSINE KINASES INHIBITORS AND THE PREPARATION METHODS AND USES THEREOF

The compounds which could inhibit protein tyrosine kinases activity or the pharmaceutical acceptable salts or hydrates thereof. The uses of the compounds in treating or preventing physiological abnormal induced by protein tyrosine kinases overexpression in mammal. The preparation methods of the compounds.

QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS

A compound of formula (I), a pharmaceutically acceptable salt, or hydrate thereof, and a method of preparing the same. A method of treating or preventing a physiological disorder caused by abnormal protein tyrosine kinase activity in a mammal comprising administering to said mammal a pharmaceutical composition comprising a compound of formula (I).

Metabolites of tricyclic amides useful for inhibition of G-protein function and methods of treatment of proliferative diseases

The present invention relates to metabolites of tricyclic amides, and structurally related compounds, represented by the structural formula (I): and pharmaceutically acceptable isomers, salts, solvates or esters of the compound of formula (I), wherein: R1 is selected from the group consisting of H and ═O; R2-R5 can be the same or different, each being independently selected from the group consisting of H, —OH, halide, —NH2 and ═O; and, the combination solid-dashed lines independently represent either single bonds or double bonds, wherein the number of combination solid-dashed lines that are double bonds is not greater than 2, and when, the double bonds are not adjacent, and when 0, one of R1-R5 is not H. Also disclosed are methods of treatment of proliferative diseases and methods for inhibiting the abnormal growth of cells, and for inhibiting farnesyl protein transferase using the novel compounds.

REVERSE HYDROXAMIC ACID DERIVATIVES

Reverse hydroxamic acid derivatives having specific structure represented by a general formula (Ia): (wherein A is a hydrogen atom or the like; Ar1 is an arylene or the like; Ar2 is an optionally substituted aryl, a heteroaryl or the

BENZOFURAN DERIVATIVE

The present invention provides a benzofuran derivative of the formula [1]: wherein x is a group of the formula: -N="or" -CH=; Y is an optionally substituted amino group, an optionally substituted cycloalkyl group or an optionally substituted saturated heterocyclic group; A is a single bond, a carbon chain optionally having a double bond within or at the end(s) of the chain, or an oxygen atom; R1 is a hydrogen atom or a halogen atom; Ring B is an optionally substituted benzene ring; and R3 is a hydrogen atom, or a pharmaceutically acceptable salt thereof, which is useful as a medicament, especially as an activated blood coagulation factor X inhibitor.

Synthesis and in vitro characterization of new growth hormone secretagogues derived from ipamorelin with dipeptidomimetic N-terminals

The structural requirements for N-terminal features for the minimal structure of growth hormone secretagogues derived from ipamorelin are investigated. It is found, that incorporation of nonpolar peptidomimetic amino acids at the N-terminal can replace the Aib-His moiety and lead to compounds with high in vitro potency with respect to their growth hormone secretagogue properties. New unnatural amino acids with double bonds, ether- linkages, and 1,3-phenylene-moieties in the backbone proved to be valuable dipeptidomimetics. Using them, growth hormone secretagogues with high potencies were obtained.

Compounds with growth hormone releasing properties

Compounds of peptide mimetic nature having the general formula I STR1 wherein a and b are independently 1 or 2, R1 and R2 are independently H or C1-6 alkyl, G and J are independently, inter alia, aromats, and D and E are independently several different groups are growth hormone secretagogous with improved bioavailability.